Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
After finishing at $68.43 in the prior trading day, CRISPR Therapeutics AG (NASDAQ: CRSP) closed at $69.15, up 1.05%. In other words, the price has increased by $1.05 from its previous closing price. On the day, 2.0 million shares were traded. CRSP stock price reached its highest trading level at $69.565 during the session, while it also had its lowest trading level at $67.0.
Ratios:
Our goal is to gain a better understanding of CRSP by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.61 and its Current Ratio is at 16.61. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.12.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, JP Morgan on September 18, 2025, initiated with a Overweight rating and assigned the stock a target price of $70.
On February 14, 2025, Evercore ISI Upgraded its rating to Outperform which previously was In-line and also upped its target price recommendation from $60 to $99.
TD Cowen Upgraded its Sell to Hold on February 12, 2025, while the target price for the stock was maintained at $35.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 14 ’25 when Kulkarni Samarth sold 4,242 shares for $66.60 per share. The transaction valued at 282,517 led to the insider holds 205,096 shares of the business.
KASINGER JAMES R. sold 1,076 shares of CRSP for $71,662 on Oct 14 ’25. The General Counsel and Secretary now owns 83,402 shares after completing the transaction at $66.60 per share. On Aug 18 ’25, another insider, Kulkarni Samarth, who serves as the Chief Executive Officer of the company, sold 13,081 shares for $58.15 each. As a result, the insider received 760,660 and left with 207,004 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRSP now has a Market Capitalization of 6289222144 and an Enterprise Value of 4783436800. For the stock, the TTM Price-to-Sale (P/S) ratio is 165.29 while its Price-to-Book (P/B) ratio in mrq is 3.57. Its current Enterprise Value per Revenue stands at 125.715 whereas that against EBITDA is -10.94.
Stock Price History:
The Beta on a monthly basis for CRSP is 1.87, which has changed by 0.4254793 over the last 52 weeks, in comparison to a change of 0.13837254 over the same period for the S&P500. Over the past 52 weeks, CRSP has reached a high of $78.48, while it has fallen to a 52-week low of $30.04. The 50-Day Moving Average of the stock is 14.32%, while the 200-Day Moving Average is calculated to be 44.42%.
Shares Statistics:
The stock has traded on average 2.86M shares per day over the past 3-months and 2907460 shares per day over the last 10 days, according to various share statistics. A total of 88.38M shares are outstanding, with a floating share count of 86.10M. Insiders hold about 5.33% of the company’s shares, while institutions hold 77.09% stake in the company. Shares short for CRSP as of 1759190400 were 21354942 with a Short Ratio of 7.46, compared to 1756425600 on 22074375. Therefore, it implies a Short% of Shares Outstanding of 21354942 and a Short% of Float of 26.51.
Earnings Estimates
CRISPR Therapeutics AG (CRSP) is currently under the scrutiny of 14.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$1.18, with high estimates of -$0.14 and low estimates of -$1.63.
Analysts are recommending an EPS of between -$4.16 and -$7.33 for the fiscal current year, implying an average EPS of -$6.26. EPS for the following year is -$4.57, with 16.0 analysts recommending between -$2.25 and -$6.71.
Revenue Estimates
A total of 22 analysts have provided revenue estimates for CRSP’s current fiscal year. The highest revenue estimate was $128.26M, while the lowest revenue estimate was $1.76M, resulting in an average revenue estimate of $29.41M. In the same quarter a year ago, actual revenue was $37.31M